Erratum: Safety of ragweed sublingual allergy immunotherapy tablets in adults with allergic rhinoconjunctivitis (Allergy and Asthma Proceedings (2012) 33, (404-410) DOI: 10.2500/aap.2012.33.3605);Safety of ragweed sublingual allergy immunotherapy tablets in adults with allergic rhinoconjunctivitis

Allergy and Asthma Proceedings

Volumn 33, Issue 5, 2012, Pages 404-410

  Nayak, Anjuli S ^a   Atiee, George J ^b   Dige, Ea ^c   Maloney, Jennifer ^d   Nolte, Hendrik ^d  

^a Wheeze and Itch Associates LLC   (United States)

^b Icon Development Solutions   (United States)

^c ALK ABELLÓ   (Denmark)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN E; PLACEBO; RAGWEED ANTIGEN;

ADULT; ALLERGIC CONJUNCTIVITIS; AMBROSIA ARTEMISIIFOLIA; ANAPHYLACTIC SHOCK; APPLICATION SITE REACTION; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; EAR PRURITUS; FEMALE; HAY FEVER; HUMAN; INTESTINE OBSTRUCTION; MAJOR CLINICAL STUDY; MALE; MOUTH EDEMA; MULTICENTER STUDY; NOSE IRRITATION; OCULAR PRURITUS; ORAL PRURITUS; OUTCOME ASSESSMENT; PERIORBITAL EDEMA; PHASE 1 CLINICAL TRIAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN PRURITUS; SUBLINGUAL IMMUNOTHERAPY; THORAX PAIN; THROAT IRRITATION; TONGUE SWELLING; TREATMENT DURATION; UNITED STATES;

EID: 84866774007     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2012.33.3600     Document Type: Erratum

References (13)

1. White JF, and Bernstein DI. Key pollen allergens in North America. Ann Allergy Asthma Immunol 91:425-435, 2003.
2. Oberhuber C, Ma Y, Wopfner N, et al. Prevalence of IgE-binding to Art v 1, Art v 4 and Amb a 1 in mugwort-allergic patients. Int Arch Allergy Immunol 145:94-101, 2008.
3. Asero R, Wopfner N, Gruber P, et al. Artemisia and Ambrosia hypersensitivity: Co-sensitization or co-recognition? Clin Exp Allergy 36:658-665, 2006.
4. Gadermaier G, Wopfner N, Wallner M, et al. Array-based profiling of ragweed and mugwort pollen allergens. Allergy 63:1543-1549, 2008.
5. Joint Task Force on Practice Parameters, American Academy of Allergy Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. Allergen immunotherapy: A practice parameter second update. J Allergy Clin Immunol 120:S25-S85, 2007.
6. ALK-Abelló. Grazax summary of product characteristics. Hørsholm, Denmark, 2009. Last revision July 2012.
7. Nelson HS. Allergen immunotherapy: Where is it now? J Allergy Clin Immunol 119:769-779, 2007.
8. Nelson HS, Nolte H, Creticos P, et al. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol 127:72-80 e2, 2011.
9. Blaiss M, Maloney J, Nolte H, et al. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol 127:64-71 e4, 2011.
10. Skoner D, Gentile D, Bush R, et al. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen. J Allergy Clin Immunol 125:660-666, 2010.
11. Bowen T, Greenbaum J, Charbonneau Y, et al. Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis. Ann Allergy Asthma Immunol 93:425-430, 2004. (Pubitemid 39507708)
12. Andre C, Perrin-Fayolle M, Grosclaude M, et al. A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis. Evidence for a dose-response relationship. Int Arch Allergy Immunol 131:111-118, 2003. (Pubitemid 36735213)
13. Creticos PS, Marsh DG, Proud D, et al. Responses to ragweedpollen nasal challenge before and after immunotherapy. J Allergy Clin Immunol 84:197-205, 1989. (Pubitemid 19223130)